Function of intracoronary recombinant human urokinase combined with tirofiban in interventional therapy of acute myocardial infarction
10.13699/j.cnki.1001-6821.2017.21.002
- VernacularTitle:重组尿激酶原联合替罗非班在急性心肌梗死介入治疗中的作用
- Author:
Qing-Qing HAO
1
;
Li-Li WANG
;
Shao-Bo AN
;
Su-Yan LI
;
Shu-Ren LI
Author Information
1. 河北省人民医院心脏中心
- Keywords:
recombinant human urokinase;
tirofiban;
myocardial infarction;
percutanous coronary intervention
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(21):2098-2100
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of intracoronary recombinant human urokinase (Pro-uk) and tirofiban in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutanous coronary intervention (PCI) by observing coronary blood flow,myocardial damage and the major adverse cardiovascular events major (MACE).Methods Ninety-eight patients with STEMI who underwent emergency PCI were randomly divided into treatment group(n =48) and control group (n =50).All patients were treated with aspirin 300 mg and ticagrelor 180 mg before coronary angiography (CAG).Treatment group was given Pro-uk 10 mg and tirofiban 10 μg · kg-1 after CAG.Control group was received PCI.The number of correction thrombolysis in myocardial infarction (TIM1) frames (CTFC) and myocardial perfusion grade (TMP) were observed after PCI.The levels of creatine kinase-MB (CK-MB) and troponin Ⅰ (cTn Ⅰ) were measured before and after operation.The major cardiac adverse events were recorded 30 days after PCI.Results The TIMI score of the arteries in treatment group was higher than that in control group.The number of corrected TIMI frame count (CTFC) in treatment group and control group were 21.97 ± 5.21,30.56 ± 4.85,with significant difference (P ＜ 0.05).The percentage of TMP level 2 and more in treatment group and control groups were 75.00％,56.00％,with significant difference (P ＜ 0.05).The levels of CK-MB and cTn Ⅰ in treatment group were (29.24 ± 8.87),(8.34 ± 2.01)ng · mL-1,had significant difference with those in control group,which were (36.93 ± 9.45),(9.36 ± 1.68)ng · mL-1 (P ＜ 0.05).There was 1 case of severe heart failure(2.08％),and there were 8 cases (16.00％) of severe heart failure and 6 cases (12.00％) of malignant arrhythmia in control group,with significant difference in two groups(P ＜ 0.05).Conclusion Intracoronary use of Pro-uk and tirofiban can alleviate myocardial injury,improve myocardial microcirculation perfusion,and decrease the MACE.
